Search Within

Guilherme Harada

  1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Meeting Abstract (5)
  2. Journal Article (2)
  3. Review (1)
Groups
  1. Department of Medicine (8)
  2. Department of Pathology and Laboratory Medicine (8)
  3. GME, Medicine (8)
  4. Graduate Medical Education (8)
  5. Solid Tumor Oncology Division (8)
  6. Thoracic Oncology (8)

More Groups

People
  1. Alexander Drilon (8)
  2. Soo Ryum Yang (6)
  3. Christina Falcon (3)
  4. Jason Chang (3)
  5. Noura Choudhury (3)
  6. Alison Schram (2)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (4)
  4. 2022 (2)
Publications
  1. Journal of Clinical Oncology (3)
  2. Annals of Oncology (1)
  3. British Journal of Cancer (1)
  4. Cancer Research (1)
  5. JTO Clinical and Research Reports (1)
  6. Nature Reviews Clinical Oncology (1)
Publishers
  1. American Society of Clinical Oncology (3)
  2. Nature Publishing Group (2)
  3. American Association for Cancer Research (1)
  4. Elsevier B.V. (1)
  5. Oxford University Press (1)

Results (8)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mucocutaneous adverse events in patients with cancer treated with the highly selective RET kinase inhibitor selpercatinib (LOXO-292)
    Journal Article

    Reingold, R. E.; Parisi, R.; Harada, G.; Moy, A. P.; Dranitsaris, G.; Francis, J. H.; Canestraro, J.; Lester, J. A.; Kaplanis, L. A.; Liu, D.; more...
    JTO Clinical and Research Reports (2025)

    Fulltext@MSK | Save
  • Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents
    Journal Article

    Roa, P.; Foglizzo, V.; Harada, G.; Repetto, M.; Kulick, A.; de Stanchina, E.; de Marchena, M.; Auwardt, S.; Sayed Ahmed, S.; Bremer, N. V.; more...
    British Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Phase II study of cabozantinib in patients with MET-altered lung cancers
    Meeting Abstract

    Harada, G.; Santini, F. C.; Repetti, R. W.; Chang, J.; Yang, S. R.; Lin, Y. T.; Moses, K. A.; Falcon, C.; Wilhelm, C. J.; Goldstein, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Genomic characterization of FGFR-altered solid tumors using a clinically annotated pan-cancer repository
    Meeting Abstract

    Choudhury, N. J.; Harada, G.; Whiting, K.; Shen, R.; Yang, S. R.; Solit, D. B.; Berger, M. F.; Dinapoli, S.; Abou-Alfa, G. K.; Iyer, G.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • ctDNA analysis of NTRK fusion and mechanisms of acquired resistance to TRK inhibitors
    Meeting Abstract

    Sivaprakasam, K.; Harada, G.; Choudhury, N. J.; Savin, C.; Shah, R. H.; Berger, M. F.; Drilon, A. E.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Rare molecular subtypes of lung cancer
    Review

    Harada, G.; Yang, S. R.; Cocco, E.; Drilon, A.
    Nature Reviews Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Splicing factor mutant lung cancers: A comprehensive molecular and clinicopathologic characterization
    Meeting Abstract

    Harada, G.; Falcon, C. J.; Santini, F. C.; Chang, J. C.; Yang, S. R.; Arcila, M. E.; Rekhtman, N.; Drilon, A.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Mechanisms of acquired resistance to TRK inhibitors
    Meeting Abstract

    Harada, G.; Choudhury, N. J.; Schram, A. M.; Rosen, E.; Murciano-Goroff, Y. R.; Falcon, C. J.; Wilhelm, C.; Kaplanis, L. A.; Liu, D.; Chang, J. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save